About Pulmonary Fibrosis Efficacy Safety Expert View Mechanism of Action Dosage RA-ILD risk calculator Previous Next Read more Read more Previous Play Next INBUILD® Trial Efficacy (autoimmune ILD patients) 15/03/2023 | Author: Boehringer Ingelheim Document ID: PC-SG-101828 EFFICACY A1-R101||A2-R101||INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients) SGOFV2023COM||INBUILD® Trial Population and Baseline Medications SGOFV2022COM||The key to managing progression in SSc-ILD patients Listen to our experts share their insights on why INBUILD® is an important study for patients with PF-ILD SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD OFEV® across different disease severities OFEV® and acute IPF exacerbations OFEV® in IPF patients with FVC ≤50% predicted Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline Progressive Pulmonary Fibrosis: focus on autoimmune ILDs Mortality data in IPF OFEV® is the first and only approved therapy for PF-ILD OFEV® reduces the risk of acute exacerbations as seen in INBUILD® RELATED CONTENT Read more PDF Consistent treatment effect of OFEV® irrespective of disease stage at which it is initiated Download Opens in new tab Read more PDF OFEV® significantly reduces the risk of AE-IPF in the pooled INPULSIS®-1 and -2 and TOMORROW trials Download Opens in new tab Read more PDF OFEV® slows FVC decline regardless of baseline FVC impairment Download Opens in new tab Read more PDF Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline Download Opens in new tab Read more PDF Progressive Pulmonary Fibrosis: focus on autoimmune ILDs Download Opens in new tab Read more PDF Exploratory analysis suggests that OFEV® may extend life expectancy and is well tolerated in patients with IPF Download Opens in new tab Pagination Load more Home Inflammation Nintedanib EFFICACY SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients)
Read more PDF Consistent treatment effect of OFEV® irrespective of disease stage at which it is initiated Download Opens in new tab
Read more PDF OFEV® significantly reduces the risk of AE-IPF in the pooled INPULSIS®-1 and -2 and TOMORROW trials Download Opens in new tab
Read more PDF OFEV® slows FVC decline regardless of baseline FVC impairment Download Opens in new tab
Read more PDF Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline Download Opens in new tab
Read more PDF Exploratory analysis suggests that OFEV® may extend life expectancy and is well tolerated in patients with IPF Download Opens in new tab